Isolated B7-H4 specific compositions and methods of use thereof

1. An isolated nucleic acid sequence encoding a chimeric antigen receptor (CAR), wherein the CAR comprises a human anti-B7-H4 antibody or antigen binding fragment thereof and a CD3 zeta signaling domain, and wherein the human anti-B7-H4 antibody or antigen binding fragment thereof comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 1-4.

2. The isolated nucleic acid sequence of claim 1 , further comprising a nucleic acid sequence encoding a co-stimulatory signaling domain.

3. The isolated nucleic acid sequence of claim 2 , wherein the co-stimulatory signaling domain is selected from the group consisting of the CD28 signaling domain, the 4-1BB signaling domain, and a combination thereof.

4. The isolated nucleic acid sequence of claim 1 , wherein the human anti-B7-H4 antibody or antigen binding fragment thereof is encoded by a nucleic acid sequence selected from the group consisting of SEQ ID NOs: 5-8.

5. An isolated chimeric antigen receptor (CAR) comprising a human anti-B7-H4 antibody or antigen binding fragment thereof and a CD3 zeta signaling domain, wherein the human anti-B7-H4 antibody or antigen binding fragment thereof comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 1-4.

6. The isolated CAR of claim 5 , further comprising a co-stimulatory signaling domain.

7. The isolated CAR of claim 6 , wherein the co-stimulatory signaling domain is selected from the group consisting of the CD28 signaling domain, the 4-1BB signaling domain, and a combination thereof.

8. A method of providing an anti-tumor immunity in a mammal, the method comprising administering to the mammal an effective amount of a genetically modified cell comprising an isolated nucleic acid sequence encoding a chimeric antigen receptor (CAR), wherein the CAR comprises a human anti-B7-H4 antibody or antigen binding fragment thereof and a CD3 zeta signaling domain, and wherein the human anti-B7-H4 antibody or antigen binding fragment thereof comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 1-4.

9. The method of claim 8 , wherein the cell is an autologous T cell.

10. The method of claim 8 , wherein the mammal is a human.

11. A method of treating a mammal having a cancer, the method comprising administering to the mammal an effective amount of a genetically modified cell comprising an isolated nucleic acid sequence encoding a chimeric antigen receptor (CAR), wherein the CAR comprises a human anti-B7-H4 antibody or antigen binding fragment thereof and a CD3 zeta signaling domain, and wherein the human anti-B7-H4 antibody or antigen binding fragment thereof comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 1-4.

12. The method of claim 11 , wherein the cancer is selected from the group consisting of liver cancer, pancreatic cancer, ovarian cancer, stomach cancer, lung cancer, endometrial cancer, hepatocellular carcinoma, and any combination thereof.